Research Advisory Panel
California law, pursuant to Health & Safety Code Sections §11480 & §11481, requires proposed research projects using certain opioid, stimulant, and hallucinogenic drugs classified as Schedule I and Schedule II Controlled Substances as their main study drug(s), to be reviewed and authorized by the Research Advisory Panel of California in the Attorney General's Office. See the Guidelines page for specific criteria.
The Research Advisory Panel primarily seeks to ensure the safety and protection of participating human research subjects and adequate security of the controlled substances used in the study. The Panel Members evaluate the scientific validity of each proposed project, and may reject proposals where the research is poorly conceived, would produce conclusions of little scientific value, or would not justify the exposure of California subjects to the risk of research.
During 2015 the Panel reviewed forty-five research study submissions. forty-three were approved by the Panel. Among the approved studies, fourteen studies were Academic research studies, two studies were Substance Abuse Treatment research protocols, and twenty-seven studies were Multi-Clinical Drug Trial research studies.
At the end of 2015, the Panel was monitoring one hundred and twenty-one research projects.
The Research Advisory Panel does NOT have any information about a State or DEA registration license for the scheduled drugs, applicants may inquire the DEA website at www.deadiversion.usdoj.gov for the DEA registration/license.
Applicants may utilize the DEA Controlled Substance Listings link for further information on controlled substance schedules.